MedTrace Logo

Polyunsaturated Fatty Acids in Patients With NAFLD.

NCT02647294 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-11

No results posted yet for this study

Summary

Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months. At the beginning and at the end of the study basic clinical and anthropometric data, as well as parameters of liver steatosis and fibrosis will be tested.

Conditions

  • NAFLD

Interventions

DIETARY_SUPPLEMENT

Maxicor

Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).

OTHER

Placebo

Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).

Sponsors & Collaborators

  • General University Hospital, Prague

    lead OTHER

Principal Investigators

  • Radan Bruha, MD · General University Hospital, Prague

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02647294 on ClinicalTrials.gov